Urinary Tract Infection Testing Market To Reach $812.01 Million By 2030

Urinary Tract Infection Testing Market Growth & Trends

The global urinary tract infection testing market is expected to reach USD 812.01 million by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 4.4% from 2023 to 2030. The urinary tract infection (UTI) testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices products.

Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S., about 250,000 cases of pyelonephritis are reported every year. In women aged 18-19, its incidence is about 28/10,000, out of which 7% of cases require hospital admission. Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000. Its recurrence is more common than other UTIs, with the recurrence rate being 5.7% in men and 9% in women.

Patients with diabetes are at increased risk of developing urinary tract infections such as acute cystitis, and therefore, the increasing global prevalence of diabetes is likely to contribute to cystitis growth. According to an NCBI article, type 2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent & severe UTIs. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. Moreover, the estimated prevalence of asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in nondiabetic females. Such factors are expected to boost the prevalence of cystitis globally.

However, due to the rise in awareness about such diseases, the demand for specialist treatment has increased in recent years. According to the U.S. Department of Health and Human Services, in the U.S., the number of practicing urologists in 2020 was 4.07 per 100,000 populations. The report further stated that due to the rise in demand, a shortage of urologists was observed, which is likely to exceed nearly 3,600 physicians by 2025. This can impede market growth in the coming years. Moreover, COVID-19 has had a detrimental impact on the industry. Individuals with UTIs have experienced substantial disruptions in testing and emergency care.

Key players are introducing novel products to strengthen their portfolios. For instance, in September 2021, OpGen, Inc. announced initiating clinical trials of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad range of pathogens and antimicrobial resistance markers directly from a urine sample. Successful clinical trials and the launch of such technologically advanced & efficient products are anticipated to drive market growth over the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a PoC and homecare setting.

 Request a free sample copy or view report summary: Urinary Tract Infection Testing Market Report

Urinary Tract Infection Testing Market Highlights

• Cystitis dominated the market in 2022, with an estimated market share of 41.42%. This can be attributed to the high incidence & recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis

• The reference laboratories segment held a share of 26.66% in 2022 attributed to the ongoing efforts of reference laboratories to enhance patient outcomes by offering diagnostic facilities at retail level.

• North America dominated the overall urinary tract infection market in terms of value. This can be attributed to better reimbursement facilities and a rise in the adoption of novel diagnostic products due to increased awareness

Urinary Tract Infection Testing Market Segmentation

Grand View Research has segmented the global urinary tract infection testing market on the basis of type, end-use, and region:

Urinary Tract Infection Testing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Urethritis

• Cystitis

• Pyelonephritis

Urinary Tract Infection Testing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• General practitioners (GPs)

• Urologists

• Urogynecologists

• Hospital Laboratories

• Reference Laboratories

• Hospital Emergency Departments

• Urgent Care

• Others

Urinary Tract Infection Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Urinary Tract Infection Testing Market

• QIAGEN

• Accelerate Diagnostics, Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

• Siemens Healthcare GmbH

• Randox Laboratories Ltd.

• Thermo Fisher Scientific, Inc.

• BIOMÉRIEUX

• T2 Biosystems, Inc.